Genetics

Photo

Article • Human resources

A pathology workforce fit for the future

The UK pathology sector faces numerous challenges as it strives to create a future medical laboratory workforce. As in many divisions of the National Health Service (NHS), this area has an ageing population yet must evolve against a backdrop of fast-developing technologies, emerging science, financial constraints and the challenge of working in tandem with the private sector. Report: Mark…

Photo

Article • IVD regulations

'We will need a lot more regulators'

The proposed EU draft IVD regulation looks set to have major implications for IVD manufacturers and laboratory-developed tests (LDTs). Replacing a current system that is inflexible, unresponsive and does not effectively protect patients, the new regulation will apply directly to all 28 EU countries and govern the manufacture and marketing of in vitro diagnostic devices (IVDs).

Photo

Cancer researchers identify new function in an old acquaintance

Cells have two different programs to safeguard them from getting out of control and developing cancer. One of them is senescence (biological aging). It puts cancer cells into a permanent sleep so they no longer divide and grow in an uncontrolled way. Now the research group led by Professor Walter Birchmeier (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) has discovered that an…

Photo

Article • Neuro Imaging

Molecular imaging brings seismic change

Molecular profiling is transforming brain cancer management and radiologists must get to grips with the upcoming paradigm that will affect the way they report findings. Renowned neuroradiologist Professor Anne G. Osborn from the University of Utah, School of Medicine, Salt Lake City, unveiled the latest advances in brain pathology during the Nikola Tesla Honorary Lecture last week at ECR…

Photo

Oocyte modification

USA - Oocyte modification to eliminate inherited mitochondrial defects in a human embryo was the subject of a globally scrutinised Food and Drug Administration (FDA) hearing held in February.

Photo

Article • 123

Earlier detection of Down’s syndrome

Down’s syndrome (also referred to as trisomy 21) is a genetic disorder caused by the presence of all or part of an extra copy of chromosome 21 in a person’s DNA. Current screening for Down’s syndrome and other trisomy conditions includes a combined test done between the 11th and 13th weeks of pregnancy.

Subscribe to Newsletter